Article
Chemistry, Multidisciplinary
Haofang Zhu, Bin Kong, Min Nie, Cheng Zhao, Rui Liu, Ying Xie, Yuanjin Zhao, Lingyun Sun
Summary: In this study, a peptide dendrimer-based microgel encapsulated with MSCs was developed using a microfluidic approach for the treatment of SLE. The microgels had tunable diameters, porous microstructures, mechanical stiffness, and immune-isolation potential. The results showed that the MSCs encapsulated microgels enhanced cellular bioactivity, immunomodulatory function, and alleviated disease symptoms.
Article
Rheumatology
Alicia Garcia-Dorta, Juan Carlos Quevedo-Abeledo, Inigo Rua-Figueroa, Antonia M. de Vera-Gonzalez, Alejandra Gonzalez-Delgado, Lilian Medina-Vega, Agustin F. Gonzalez-Rivero, Felix Francisco-Hernandez, Miguel A. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: The study found that markers of beta-cell secretion were higher in SLE patients compared to controls, especially in patients undergoing glucocorticoid therapy. This disproportionate hyperproinsulinemia may be associated with damage caused by the disease.
Article
Immunology
Lingshu Zhang, Ying Shi, Jingyao Zhang, Jing Wu, Wei Jiang
Summary: Seizures are a life-threatening complication of neuropsychiatric systemic lupus erythematosus (NPSLE) and are often associated with poor outcomes. Cyclophosphamide immunotherapy is the main treatment for NPSLE. We report a rare case of a NPSLE patient who developed seizures after receiving low-dose cyclophosphamide. The exact mechanism of cyclophosphamide-induced seizures is not well understood, but it is thought to be related to the drug's unique pharmacology. Clinicians should be aware of this complication and carefully adjust immunosuppressive regimens.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Eric F. Morand, Edward M. Vital, Michelle Petri, Ronald van Vollenhoven, Daniel J. Wallace, Marta Mosca, Richard A. Furie, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Bochao Jia, Brenda Crowe, Inmaculada de la Torre, Thomas Doerner
Summary: The objective of this study was to evaluate the efficacy and safety of baricitinib in patients with active SLE. The results showed that baricitinib 4 mg significantly improved SLE disease activity compared with placebo, but key secondary endpoints were not met. The safety profile of baricitinib in patients with SLE was consistent with the known safety profile.
Article
Rheumatology
Diane L. Kamen, Julie A. Birt, Monica A. Hadi, Elizabeth Gibbons, Donald M. Bushnell, Ren Yu, Laure A. Delbecque, Kirstin Griffing, Anca Askanase
Summary: Many people with SLE experience joint symptoms such as pain, swelling, and stiffness, which can impact physical functioning and work disability. A survey was conducted on adults with SLE to examine the burden and impact of joint symptoms.
Review
Oncology
Kaichi Kaneko, Hao Chen, Matthew Kaufman, Isaak Sverdlov, Emily M. Stein, Kyung-Hyun Park-Min
Summary: Osteonecrosis is a complex and devastating complication of systemic lupus erythematosus, with variable prevalence in SLE patients. The use of high-dose glucocorticoid therapy is strongly associated with the development of osteonecrosis in SLE patients, although the exact pathophysiology and risk factors for osteonecrosis in this population are not fully understood.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Genetics & Heredity
Huiyan Li, Pingting Yang
Summary: This study analyzed SLE expression data and identified modules associated with neutrophils. Two molecular subtypes of SLE were reclassified based on identified biomarkers, revealing significant differences in immunological characteristics and potential gene targets. The study also revealed associations between biomarkers and metabolic pathways, providing insights for immunotherapy.
BMC MEDICAL GENOMICS
(2022)
Review
Biochemistry & Molecular Biology
Valeria Rella, Cinzia Rotondo, Alberto Altomare, Francesco Paolo Cantatore, Addolorata Corrado
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical manifestations. Dysregulation of the immune system due to genetic, hormonal, and environmental factors can lead to various complications, including bone involvement such as osteoporosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Shunxiang Li, Huihua Ding, Ziheng Qi, Jing Yang, Jingyi Huang, Lin Huang, Mengji Zhang, Yuanjia Tang, Nan Shen, Kun Qian, Qiang Guo, Jingjing Wan
Summary: Serum metabolic fingerprints can be used for disease diagnosis and biomarker discovery. By analyzing the serum metabolic fingerprints of systemic lupus erythematosus (SLE) patients and healthy controls, early diagnosis and precision medicine for SLE can be achieved. This study identified the unique metabolic pattern of SLE patients and screened out a panel of metabolic biomarkers.
Article
Rheumatology
Manuel Francisco Ugarte-Gil, John Hanly, Murray Urowitz, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Ann Elaine Clarke, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Ken Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Bernardo A. Pons-Estel, Graciela S. Alarcon
Summary: This study investigated the impact of different definitions of remission and low disease activity on damage accrual in patients with lupus. The results show that both remission on-treatment and off-treatment, as well as low disease activity and modified lupus low disease activity, are associated with less damage accrual.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Immunology
Nicolas Schall, Laura Talamini, Maud Wilhelm, Evelyne Jouvin-Marche, Sylviane Muller
Summary: In systemic lupus erythematosus, T cells display multiple abnormalities. P140, a synthetic peptide, can deplete these abnormal cells and restore normal immune homeostasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Johan Frostegard
Summary: The prognosis in systemic lupus erythematosus (SLE) has improved, but cardiovascular disease (CVD) still remains a significant clinical problem. Atherosclerosis and antiphospholipid antibody syndrome are the main underlying causes of CVD in SLE. Inflammation and low levels of anti-phosphorylcholine also contribute to the increased risk of CVD in SLE. Close monitoring and treatment of both traditional and non-traditional risk factors are important.
JOURNAL OF INTERNAL MEDICINE
(2023)
Review
Immunology
Jiaxuan Chen, Shuzhen Liao, Wanxian Pang, Fengbiao Guo, Lawei Yang, Hua-feng Liu, Qingjun Pan
Summary: Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease that primarily affects women. This review explores the mechanisms of SLE pathogenesis, focusing on the impact of lifestyle factors. Studies have found associations between diet, cigarette smoking, ultraviolet radiation exposure, alcohol and caffeine-rich beverage consumption, and SLE susceptibility. The review summarizes these relationships and outlines directions for future research.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
W. Winn Chatham, Richard Furie, Amit Saxena, Philip Brohawn, Erik Schwetje, Gabriel Abreu, Raj Tummala
Summary: Long-term treatment with anifrolumab shows acceptable safety profile and sustained improvement in disease activity, health-related quality of life, and serologic measures for patients with moderate-to-severe systemic lupus erythematosus.
ARTHRITIS & RHEUMATOLOGY
(2021)